Maxalt Smelt

Rizatriptan, the active ingredient in Maxalt Smelt, is a Triptan (5‑HT1B/1D receptor agonist) presented as an oral tablet for oral use. It is indicated for the acute treatment of migraine attacks in adults.

GNH USA supplies Maxalt Smelt as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. All batches are manufactured under GMP guidelines and undergo rigorous quality testing before distribution. The company provides reliable logistics and supports regulatory documentation for importers in multiple regions globally.

Rizatriptan acts on the trigeminal vascular system to relieve migraine symptoms.

- Migraine without aura: provides rapid relief of headache pain, nausea, and photophobia. - Migraine with aura: alleviates the headache phase after aura resolution. - Acute episodic migraine: reduces the need for additional rescue medication when taken early in an attack.

Rizatriptan may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea - Dizziness - Dry mouth - Fatigue

Serious or Rare Side Effects: - Chest pain or tightness - Serotonin syndrome - Severe allergic reaction (anaphylaxis)

Before prescribing Rizatriptan, consider the following precautions to ensure safe use.

- Cardiovascular history: evaluate for coronary artery disease, uncontrolled hypertension, or cerebrovascular disorders. - Concomitant serotonergic agents: avoid co‑administration with SSRIs, SNRIs, MAO inhibitors, or other triptans due to serotonin syndrome risk. - Pregnancy and lactation: safety not established; use only if potential benefit justifies potential risk. - Age considerations: not recommended for children; efficacy and safety established primarily in adults. - Drug interactions: review all current medications, especially ergot derivatives and certain antihypertensives. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture and light.

Rizatriptan can interact with several drug classes; awareness of major and moderate interactions helps prevent adverse events.

Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension and serotonin syndrome. - Other triptans or ergotamine derivatives: additive vasoconstriction may occur. - SSRIs, SNRIs, or other serotonergic antidepressants: increase serotonin syndrome risk. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): elevate rizatriptan plasma concentrations.

Moderate Interactions (Monitor Closely): - Antihypertensive agents (beta‑blockers, calcium channel blockers): may enhance blood pressure lowering. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce rizatriptan effectiveness. - NSAIDs: combined use may raise risk of cardiovascular side effects.